4272.T

• Overall Aggregate Performance

  • FY2025 Q3 cumulative total revenue hit 174.6 billion yen, a 6.6 billion yen year-on-year increase, marking an all-time high for the 9-month cumulative period. Operating profit was 16.3 billion yen (1.8 billion yen YoY decrease), net income attributable to parent was 17.3 billion yen (4.0 billion yen YoY increase).
  • Gross margin declined 2.4 percentage points YoY, leading to total segment operating profit of 23.6 billion yen. Progress against full-year guidance: revenue 73%, operating profit 77%, ordinary profit 89%, net income 85%, which is in line with management expectations for a 75% progress target for the first three quarters.
  • Total assets increased 32.3 billion yen from the end of last fiscal year to 406.0 billion yen, driven by a 18.5 billion yen increase in inventory and 11.6 billion yen increase in fixed assets. Equity grew 5.5 billion yen YoY to 273.0 billion yen, with an equity ratio of 67.2% (60% is the long-term target), and projected full-year ROE of 7.7%.
  • Cumulative YTD R&D expense is 8.5 billion yen, capital expenditure is 10.8 billion yen, depreciation and amortization is 11.4 billion yen; projected full-year figures are 13.7 billion yen, 20.1 billion yen, and 16.0 billion yen respectively.
  • Shareholder return policy remains unchanged: 40%+ payout ratio with progressive dividends. Full-year projected total payout ratio is 129.4%, payout ratio 44.2%, with a planned annual dividend of 60 yen per share unchanged from last year.

• Product & Pipeline Updates

  • Life Science: Launched new lung cancer drug Ivtrology in November, which is seeing faster-than-expected adoption and is on track to beat initial sales forecasts. Bevacizumab BS grew market share from 50% in September to 58% in December, Adalimumab BS grew from 14% to 17% over the same period. New generic anti-cancer drug Abiraterone Tablets 250mg "NK" was also launched. The drug pipeline: Portrazza is in Phase II for indication expansion to EGFR amplification-positive unresectable recurrent esophageal and gastric cancer; Alaglio is now in Phase II for indication expansion to cancer visualization during ovarian cancer resection; VECanDx diagnostic agent is in trial preparation.
  • Mobility & Imaging: Safety Systems is expanding high-priority growth markets, with local staffing in India and ongoing expansion through Korean customer partnerships. Squinb for current interrupters is on track to launch business in China this fiscal year. Fine Chemicals: Functional materials for semiconductors are on track to hit all-time full-year revenue, with catalysts also expected to deliver full-year revenue growth and an all-time annual sales high.

• Full-year FY2025 guidance remains unchanged from the November announcement, despite uneven Q4 progress across business segments. Management has adjusted segment-level revenue and operating profit forecasts to reflect these uneven trends.
• Mobility & Imaging: Q4 is expected to be weak due to raw material price hikes and inventory adjustments. Safety Systems will continue pushing price pass-through, with management top leadership leading escalated top-level meetings with customers to advance negotiations covering all cost increase and reduction initiatives, rolling out the practice gradually. China automotive growth is expected to continue despite near-term policy-driven slowdown. Polatechno expects continued weak demand for liquid crystal projector components, with head-up display light shields to be weak in early Q4 then recover in the second half.
• Fine Chemicals: Semiconductor-related businesses will remain strong, while consumer and industrial inkjet pigments will stay soft in Q4. Catalyst business will see concentrated sales in Q4 (8.3 billion yen planned), delivering full-year revenue growth and an all-time annual sales high. Full-year segment operating profit will grow driven by higher sales in functional materials and catalysts. Functional materials growth is supported by upwardly revised semiconductor market forecasts from WSTS, particularly for automotive microcontrollers, analog, and discrete semiconductors, and growth is expected to continue into next fiscal year with no negative customer signals to date.
• Life Science: Generic anti-cancer drugs, new drugs, and biosimilars are expected to remain strong through Q4, with the agro business also continuing solid performance. Q4 segment operating profit will see a mild sequential decrease due to planned R&D expense recognition for pharmaceutical business, but will still increase year-on-year. Ivtrology is on track to exceed initial sales projections.
• Capital expenditure: Full-year FY2025 capex guidance is revised down from 24.0 billion yen to 20.1 billion yen, a 4.0 billion yen reduction, driven by KMY (Malaysia) investment scope review and carry-over of some projects to future fiscal years.

1. Mobility & Imaging Business Domain: Revenue of 70.4 billion yen, year-on-year growth; segment operating profit of 7.9 billion yen, a 2.9 billion yen year-on-year decrease. Its overseas subsidiaries KSE (Czech Republic) grew revenue 1.3 billion yen year-on-year, KSH (China) grew 2.5 billion yen year-on-year, while KSM (Mexico) decreased revenue due to lower vehicle production from US tariff impacts. Within the domain, Safety Systems business grew revenue after resolving production shutdown impacts from past type certification irregularities in domestic operations, with continued growth in China sales, but saw profit decline from raw material price hikes (gold, gunpowder) and unfavorable foreign exchange for procurement. Polatechno business grew revenue for head-up display light shields, but saw overall revenue decline due to product discontinuation for liquid crystal projector components and lower demand from key customer inventory adjustments for X-ray analyzer components, dragging down profit. 2. Fine Chemicals Business Domain: Revenue of 50.1 billion yen, a 0.4 billion yen year-on-year decrease; segment operating profit of 7.0 billion yen, a 1.0 billion yen year-on-year decrease. Within the domain, functional materials saw strong growth driven by expanding semiconductor market conditions for advanced (AI, high-end server) and recovering general-purpose semiconductor segments; pigment materials were strong in Q1 but weakened after Q2 due to adjustments for consumer and industrial inkjet pigments; catalyst business was weak through Q1-Q3, with 8.3 billion yen in revenue planned for Q4 per its seasonal sales concentration characteristic. Profit through Q3 was dragged down by lower sales in pigment and catalyst businesses. 3. Life Science Business Domain: Revenue of 54.1 billion yen, year-on-year growth; segment operating profit of 8.7 billion yen, a 2.7 billion yen year-on-year increase. Biosimilars (BS) account for 12.5 billion yen of total revenue, growing 4.1 billion yen year-on-year. Revenue contribution % by segment: Mobility & Imaging 40.3%, Fine Chemicals 28.7%, Life Science 31.0%.

• Raw material cost volatility: Gold prices have risen significantly since the November guidance setting, accounting for a large share of total raw material cost increases for Safety Systems business, and further upside price risk remains as gold prices are exposed to commodity market fluctuations. Global raw material cost inflation overall has pushed up total annual raw material costs by 3% for Safety Systems.
• Demand headwinds: China new energy vehicle incentive policies expired at the end of December 2025, leading to front-loaded rush demand in Q3 and a projected significant slowdown in January and February 2026 that will weigh on Q4 Safety Systems sales. Industrial inkjet continues to be impacted by US tariffs, with weaker-than-expected recovery in printer manufacturer sales leaving the segment softer than initial forecasts through Q4. KSM (Mexico) is facing demand declines from lower vehicle production due to US tariffs.
• Margin pressure: Gross margin has declined 2.4 percentage points year-to-date, and price pass-through for raw material cost increases is still ongoing, with only 55% of total cost increases recovered as of Q3 (global aggregate).

Q: What are the growth drivers for Safety Systems business including international expansion, specifically the outlook for India and squib for current interrupters? Is supply for India planned from Malaysia, and will current interrupter business launch this fiscal year?

A: India is expected to see strong market growth and is a key priority expansion market. Nippon Kayaku already has local expats stationed there collecting market data and advancing sales, with a focus on expansion through Korean customers, which is expected to drive long-term growth. Supply is planned to be centered in Malaysia pending local demand scale. Current interrupter squib business is advancing sales with Chinese customers, and business will launch this fiscal year, with further growth in new orders expected going forward. That confirms business will start this fiscal year.

Q: When will industrial inkjet recover, and what is the long-term outlook for the segment? Is recovery expected in the early part of next fiscal year?

A: Consumer inkjet pigments started recovering gradually in Q4 after struggling through Q3 due to US tariff impacts, but recovery is slower than initially expected because printer manufacturers are facing weaker-than-projected end demand. Industrial inkjet (Nippon Kayaku's focus is water-based pigment inks) is also facing headwinds from US tariffs in Q3 and Q4, but the long-term growth outlook remains positive supported by ongoing industry digitalization. Recovery is expected in the early part of next fiscal year.

Q: Is the large Q4 catalyst sales increase fairly certain, is it the main driver of the Q4 Fine Chemicals profit increase, what is behind the upward revision to functional materials sales, and will this growth continue next year?

A: The Q4 catalyst sales and profit increase is as described, and functional materials are also seeing growth. The main driver of upward functional materials revisions is the WSTS upward revision to the global semiconductor outlook in December, particularly for automotive micro, analog, and discrete components, which has lifted demand for semiconductor-related products including sealing materials. No negative signals for next year's growth have been received from customers so growth is expected to continue as planned.

Q: Mobility & Imaging is tracking below initial forecasts, will it improve and recover upward next year? How will the company handle gold price increases, will price pass-through be pushed with top-level meetings covering all customers?

A: Gold prices have risen sharply since November guidance, so gold accounts for a very large share of total raw material cost increases. While gold prices could rise further and are exposed to unpredictable market volatility, the company is actively pushing for selling price increases, and is also pursuing cost reduction initiatives with suppliers across all other raw materials to offset the impact of higher gold prices. Top-level meetings with customers have already started with select clients, and will be gradually expanded. These meetings cover not just gold price pass-through, but all raw material cost inflation and joint cost reduction initiatives, driven by senior leadership and supported by on-the-ground collaboration with customers.

Q: Safety Systems is tracking below plan, can we expect strong sales growth from the strengthened cylinder product line next year and beyond?

A: The main reason for the current downside miss is China: the market was strong through Q3, but started declining mid-Q3 and will be very weak in Q4. This is driven by the expiration of new energy vehicle tax cuts and subsidy incentives at the end of December, which pulled demand forward into November (with some regions running out of subsidy budget earlier than expected), leading to a negative payback in January and February. Demand is expected to recover starting around March ahead of April new vehicle sales, so the slowdown is not expected to persist.

Q: Life Science has seen strong 12.3% YoY revenue growth and 44.6% YoY operating profit growth, is this driven mostly by biosimilar growth, and are there other contributing factors? Why are other generics growing?

A: Biosimilars are indeed growing very strongly and are a core driver of growth, but other generic products have also grown and contributed to both top-line and bottom-line expansion. The growth in other generics is driven by market share gains from alternative supply as other manufacturers exit the market for several anti-cancer generic products, which Nippon Kayaku already produces and where there are few existing market participants.

Q: How much further can bevacizumab BS and adalimumab BS grow their market shares?

A: A specific target cannot be given, but Japan's Ministry of Health, Labour and Welfare has a national policy target for 60% of all biologic components to have biosimilar market share of 80% or higher. Nippon Kayaku is preparing from a stable supply perspective to fully meet this policy-driven market expansion, and is standing by to support share growth as switching progresses at hospital customers.

Q: Can you share details on the two major capex projects: the inflator project at KSH China and the integrated quality assurance building at Takasaki Works, including investment amount, scope and timeline?

A: The integrated quality assurance building at Takasaki Works is being built to strengthen quality assurance for pharmaceuticals in line with industry requirements, as production volumes have grown alongside market share gains. The facility is under construction, scheduled for completion in FY2026, with validation work after completion and full operation targeted for FY2027. The total investment amount is 4.2 billion yen, it is the first dedicated integrated quality assurance building for Nippon Kayaku, and will focus on quality control for the company's core low-molecular-weight anti-cancer drugs (biosimilars are handled at separate existing facilities). For KSH China, the project is a land extension for capacity expansion, with investment approved this fiscal year and production start targeted for 2 to 3 years from approval, around 2027. The project covers both inflator capacity expansion and the first domestic squib production in China, with squib production starting in 2027 and inflator capacity coming online earlier.

Q: Why has full-year capex guidance been cut by 4.0 billion yen from 3 months ago? Does the Malaysia investment review mean a smaller capacity increase than originally planned? When will the Malaysia investment be completed?

A: The reduction comes from two main factors: a review of the KMY (Malaysia) Safety Systems investment project, and the carry-over of some projects across all business segments to future fiscal years. The project was put on hold temporarily to adjust global supply allocation to avoid excess capacity across the global production network. The core portion of the Malaysia investment, carried over from last fiscal year, is almost complete already.

Q: What is the progress of price pass-through for raw material cost increases, what share of cost increases has been passed through as of Q3? Can we expect further price increase benefits in Q4 and next fiscal year?

A: For Safety Systems, total raw material cost increases this fiscal year have lifted total annual raw material costs by approximately 3%. Approximately 55% of these cost increases have been recovered through selling price increases, which is up from 40% (previous guidance for domestic operations only, this 55% is global aggregate). Progress has accelerated significantly in Q3, and further price increase benefits are expected in Q4 and next fiscal year.

Q: What was the foreign exchange impact on the Q3 cumulative results?

A: Measured against last year's average exchange rate, the total impact on revenue was 0.18 billion yen, and on operating profit was 0.2 billion yen.

Q: Why is profit growing faster than sales for Fine Chemicals in the latest revision (sales +1.0 billion yen, profit +0.8 billion yen)? Is functional materials upside included in this revision?

A: The dynamic is partially due to sales mix: Teikoku Taping System, a group subsidiary, sold fewer units than planned in Q3, with sales pushed into Q4, so Q4 will see higher sales and profit for that business, leading to a full-segment profit upgrade concentrated in Q4. Functional materials does see upward revisions, but this is offset by continued weakness in pigment materials (including industrial inkjet) in Q4, so the net overall revision reflects that net adjustment.